BioMarin reports Q3 non-GAAP EPS 46c, consensus 22c

Reports Q3 revenue $581.3M, consensus $608.33M. “Results in the quarter drove double-digit revenue growth year-over-year and support BioMarin’s full-year 2023 revenue and profitability objectives, set at the beginning of the year,” said CEO Jean-Jacques Bienaime. “…In parallel with exceptional commercial and regulatory execution of VOXZOGO during the quarter, we concluded key reimbursement steps to facilitate ROCTAVIAN treatment in Europe and the U.S. All together, these developments drive our expectation that total BioMarin revenues will approach $3B in 2024…In the U.S. since gaining FDA approval of ROCTAVIAN on June 29, 2023, the commercial team has been building the reimbursement network to facilitate patient access, setting the stage for meaningful uptake of ROCTAVIAN in 2024.”